Asthma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Asthma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month10 studies across 4 companies, in the next 180 days.
September 2026 5
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyNCT06033833Percentage of participants with treatment-emergent adverse events | Phase 2 | Active, not recruiting | 2026-09-29 | in 40 d | 2026-05-20 |
| APGE | Apogee Therapeutics, Inc. | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2026-02-17 |
| AZN | AstraZeneca | Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry StudyNCT06521229observationalTo describe the baseline demographic characteristics of outpatients with uncontrolled asthma in the Russian Federation in all patients and in the cohort of patients receiving fixed-dose combination (FDC) budesonide/salbutamol on Visit 2 | — | Recruiting | 2026-09-30 | in 41 d | 2026-04-20 |
| AZN | AstraZeneca | Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaNCT06566885observationalChange in ACQ-5 score from baseline | — | Active, not recruiting | 2026-09-30 | in 41 d | 2026-05-12 |
| AZN | AstraZeneca | An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885observationalthe proportion of days covered (PDC) with asthma biologics during 52 weeks | — | Active, not recruiting | 2026-09-30 | in 41 d | 2026-08-12 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese PopulationNCT06419413observationalDescriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables. | — | Recruiting | 2026-10-08 | in 49 d | 2026-08-18 |
| AZN | AstraZeneca | Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsNCT03953300The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies | Phase 4 | Active, not recruiting | 2026-10-19 | in 60 d | 2026-07-28 |
November 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INCY | Incyte Corporation | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1) | Phase 2 | Active, not recruiting | 2026-11-20 | in 92 d | 2026-07-07 |
| AZN | AstraZeneca | Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)NCT07218172observationalAsthma related characteristics | — | Active, not recruiting | 2026-11-30 | in 102 d | 2026-06-15 |
February 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareNCT06422689Asthma exacerbation | Phase 4 | Active, not recruiting | 2027-02-03 | in 167 d | 2026-07-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Asthma
most recently updated first563 studies match. Showing the first 100 of 563 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentNCT07444567Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab | Phase 3 | Recruiting | Drug: Benralizumab | Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES) | 230 | 2026-07-24 | 2030-01-03 | in 1,232 d | 2026-08-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaNCT07772921Annualized asthma exacerbation rate over 52 weeks | Phase 3 | Not yet recruiting | Drug: tilrekimig · Other: Placebo | Asthma | 1,100 | 2026-08-24 | 2029-06-12 | in 1,027 d | 2026-08-19 |
| AZN | AstraZeneca | — | A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese PopulationNCT06419413observationalDescriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables. | — | Recruiting | — | Asthma | 355 | 2024-01-08 | 2026-10-08 | in 49 d | 2026-08-18 |
| AZN | AstraZeneca | — | A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaNCT06023589Annualized severe asthma exacerbation rate (AAER) | Phase 3 | Recruiting | Biological: Tezepelumab · Other: Placebo | Asthma | 231 | 2023-08-24 | 2028-05-31 | in 650 d | 2026-08-17 |
| GENB | Generate Biomedicines | $2.0B | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)NCT07276724To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma. | Phase 3 | Recruiting | Drug: GB-0895, Placebo | Severe Asthma | 786 | 2025-12-03 | Dec 2028 | ≤ 864 d | 2026-08-17 |
| KYMR | Kymera Therapeutics, Inc. | $10.1B | A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654Change from baseline in pre-bronchodilator FEV1 | Phase 2 | Recruiting | Drug: KT-621 · Other: Placebo | Eosinophilic Asthma | 264 | 2026-01-28 | Dec 2027 | ≤ 498 d | 2026-08-17 |
| GENB | Generate Biomedicines | $2.0B | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)NCT07359846To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma. | Phase 3 | Recruiting | Drug: GB-0895, Placebo | Severe Asthma | 786 | 2026-01-20 | Jan 2029 | ≤ 895 d | 2026-08-17 |
| SNY | Sanofi | — | Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)NCT06191315Part A: Annualized rate of severe asthma exacerbations during the 52-week treatment period | Phase 3 | Enrolling by invitation | Drug: Dupilumab, Placebo | Wheezing, Asthma | 90 | 2024-01-03 | 2028-12-21 | in 854 d | 2026-08-13 |
| AZN | AstraZeneca | — | Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaNCT06307665Annualized rate of severe asthma exacerbations (AAER) | Phase 3 | Recruiting | Combination product: BDA MDI, AS MDI | Asthma | 440 | 2024-05-20 | 2027-10-13 | in 419 d | 2026-08-13 |
| AZN | AstraZeneca | — | STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaNCT06465485To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen in the overall patient populationa and by subgroups of baseline background therapy | Phase 3 | Completed | Drug: Benralizumab | Severe Eosinophilic Asthma | 504 | 2024-02-28 | 2026-05-13actual | — | 2026-08-13 |
| SNY | Sanofi | — | Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE) | Phase 2 | Enrolling by invitation | Drug: Lunsekimig | Asthma | 900 | 2024-09-30 | 2031-01-20 | in 1,614 d | 2026-08-13 |
| AZN | AstraZeneca | — | ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in RussiaNCT07399665observational1. Change in endoscopic status of CRSwNP based on NPS | — | Recruiting | — | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Asthma | 110 | 2025-12-25 | 2028-03-31 | in 589 d | 2026-08-13 |
| SNY | Sanofi | — | A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical PracticeNCT07556159observationalPart 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities | — | Recruiting | Other: Procedure: Investigational Procedures, Procedure: Investigational Procedures | Asthma | 2,500 | 2026-04-01 | 2029-04-04 | in 958 d | 2026-08-13 |
| AZN | AstraZeneca | — | An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma PatientsNCT06605885observationalthe proportion of days covered (PDC) with asthma biologics during 52 weeks | — | Active, not recruiting | — | Asthma | 202 | 2024-11-14 | 2026-09-30 | in 41 d | 2026-08-12 |
| AMGN | Amgen | $229.9B | A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaNCT06376045Annualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment Period | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: Rocatinlimab, Placebo | Asthma | 317 | 2024-05-24 | 2026-05-14actual | — | 2026-08-11 |
| AZN | AstraZeneca | — | A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaNCT06471257Time to first severe asthma exacerbation | Phase 3 | Recruiting | Combination product: Budesonide/Albuterol metered dose inhaler, MDI, Albuterol sulfate metered dose inhaler, MDI | Asthma | 1,000 | 2024-06-17 | 2027-10-04 | in 410 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe AsthmaNCT07219173Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment | Phase 2 | Recruiting | Drug: Brenipatide, Brenipatide, Placebo | Asthma | 531 | 2025-10-22 | Apr 2028 | ≤ 619 d | 2026-08-07 |
| AZN | AstraZeneca | — | Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsNCT03953300The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies | Phase 4 | Active, not recruiting | Biological: Benralizumab, Placebo | Asthma | 75 | 2019-10-08 | 2026-10-19 | in 60 d | 2026-07-28 |
| AZN | AstraZeneca | — | Fasenra Pediatric Japan Post-Marketing Study(PMS)NCT06427876observationalIncidence of ADRs | — | Active, not recruiting | — | Bronchial Asthma | 40 | 2024-07-16 | 2028-12-31 | in 864 d | 2026-07-27 |
| AZN | AstraZeneca | — | Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 AgonistNCT07718724Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 24 | Not applicable | Not yet recruiting | Behavioral: Intervention group | Uncontrolled Asthma | 540 | 2026-08-15 | 2028-04-30 | in 619 d | 2026-07-22 |
| SNY | Sanofi | — | Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)NCT04550962observationalBaseline Characteristics: Socio-demographics | — | Completed | Drug: Dupilumab SAR231893 | Asthma | 376 | 2020-11-02 | 2026-06-18actual | — | 2026-07-20 |
| ALK-B.CO | ALK-Abelló A/S | — | Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and AsthmaNCT05476484observationalSymptom-relieving medication use for allergic rhinitis | — | Completed | Drug: SQ SLIT-tablet | Allergic Rhinitis, Asthma, Allergy | 46,196 | 2022-04-01 | 2024-06-30actual | — | 2026-07-20 |
| AZN | AstraZeneca | — | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263Annualised rate of severe asthma exacerbations | Phase 2 | Recruiting | Drug: Tozorakimab, Placebo | Asthma | 540 | 2025-03-26 | 2027-06-07 | in 291 d | 2026-07-20 |
| AZN | AstraZeneca | — | Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in ItalyNCT06948396observationalDemographic and Clinic characterization | — | Active, not recruiting | Biological: Tezepelumab | Asthma | 315 | 2025-06-25 | 2027-05-30 | in 283 d | 2026-07-20 |
| AZN | AstraZeneca | — | A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaNCT05692180Time to first asthma exacerbation | Phase 3 | Active, not recruiting | Drug: Benralizumab, Placebo | Asthma | 94 | 2023-04-05 | 2030-05-05 | in 1,354 d | 2026-07-17 |
| AZN | AstraZeneca | — | Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United StatesNCT05329194results2026-07-16Annualized Asthma Exacerbation Rate (AAER) | Phase 4 | Completed | Drug: Tezepelumab | Asthma | 286 | 2022-04-29 | 2025-10-01actual | — | 2026-07-16 |
| AZN | AstraZeneca | — | Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareNCT06422689Asthma exacerbation | Phase 4 | Active, not recruiting | Drug: Albuterol and budesonide inhalation aerosol | Asthma | 1,511 | 2024-05-10 | 2027-02-03 | in 167 d | 2026-07-16 |
| AZN | AstraZeneca | — | A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With AsthmaNCT07433569Maximum observed plasma concentration (Cmax) | Phase 1 | Completed | Combination product: Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI | Asthma | 16 | 2026-03-05 | 2026-06-26actual | — | 2026-07-15 |
| SPRY | ARS Pharmaceuticals, Inc. | $627M | Administration of ARS-1 or Albuterol in Subjects With Persistent AsthmaNCT05363670results2026-07-14Effect of ARS-1 Versus Albuterol and Placebo | Phase 2 | Completed | Drug: ARS-1 1 mg, Albuterol MDI, Placebo, ARS-1 2mg | Asthma | 18 | 2022-07-28 | 2024-02-02actual | — | 2026-07-14 |
| AZN | AstraZeneca | — | A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in ItalyNCT07214753observationalNumber and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition | — | Recruiting | Biological: benralizumab | Severe Eosinophilic Asthma | 335 | 2025-12-20 | 2028-12-31 | in 864 d | 2026-07-08 |
| INCY | Incyte Corporation | $24.7B | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1) | Phase 2 | Active, not recruiting | Drug: povorcitinib, ICS-LABA · Other: placebo | Moderate to Severe Asthma | 247 | 2023-07-11 | 2026-11-20 | in 92 d | 2026-07-07 |
| AZN | AstraZeneca | — | Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)NCT04609904results2026-07-02Change From Baseline in FEV1 AUC0-3 (L) at Week 24 | Phase 3 | Completed | Drug: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg | Asthma | 2,187 | 2021-03-01 | 2025-03-20actual | — | 2026-07-02 |
| SNY | Sanofi | — | Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319Annualized rate of asthma exacerbation events | Phase 2 | Active, not recruiting | Drug: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol | Asthma | 556 | 2024-11-07 | 2027-06-21 | in 305 d | 2026-07-01 |
| AZN | AstraZeneca | — | Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)NCT04609878results2026-06-30Change From Baseline in FEV1 AUC0-3 (L) at Week 24 | Phase 3 | Completed | Drug: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg | Asthma | 2,274 | 2020-12-15 | 2025-03-21actual | — | 2026-06-30 |
| PFE | Pfizer | $155.3B | A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaNCT07660731Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: PF-08103402, Placebo, Midazolam | Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma | 139 | 2026-06-17 | 2027-06-18 | in 302 d | 2026-06-29 |
| AZN | AstraZeneca | — | Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabNCT07363642To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma control | Phase 3 | Recruiting | Drug: Tezepelumab | Severe Asthma | 400 | 2026-01-28 | 2027-08-07 | in 352 d | 2026-06-25 |
| AZN | AstraZeneca | — | A Non-interventional, Prospective Study With BenralizumabNCT06422078observationalChange in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose | — | Recruiting | — | Asthma, Bronchial | 300 | 2024-07-25 | 2027-12-31 | in 498 d | 2026-06-24 |
| AZN | AstraZeneca | — | Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)NCT06472310observationalTo characterise the profile of routine therapy used for patients with uncontrolled SA not receiving biological therapy in proportion of patients receiving different classes of drugs will be calculated | — | Recruiting | — | Severe Asthma | 5,000 | 2024-06-06 | 2027-06-30 | in 314 d | 2026-06-24 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaNCT07241546Change from Baseline Over Time in Maximum Area of Reactance | Phase 2 | Recruiting | Drug: ARO-RAGE, Placebo | Asthma | 36 | 2026-03-30 | Dec 2027 | ≤ 498 d | 2026-06-23 |
| AZN | AstraZeneca | — | Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent AsthmaNCT05398263results2026-06-18Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control. | Phase 3 | Terminatedsponsor's stated reason: The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety concerns. | Biological: Tezepelumab · Other: Placebo | Asthma | 125 | 2022-08-09 | 2025-03-24actual | — | 2026-06-18 |
| AMGN | Amgen | $229.9B | A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaNCT06637371Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: AMG 691, Placebo | Asthma | 21 | 2024-10-16 | 2027-04-10 | in 233 d | 2026-06-17 |
| AZN | AstraZeneca | — | Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.NCT06473779Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase. | Phase 3 | Active, not recruiting | Combination product: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol | Severe Asthma | 326 | 2024-09-30 | 2027-06-25 | in 309 d | 2026-06-15 |
| AZN | AstraZeneca | — | EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in GreeceNCT06724575observationalChange in the ACQ-6 score at baseline and up to 104 weeks post-index | — | Active, not recruiting | — | Asthma | 155 | 2024-12-17 | 2028-06-30 | in 680 d | 2026-06-15 |
| AZN | AstraZeneca | — | Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)NCT07218172observationalAsthma related characteristics | — | Active, not recruiting | — | Severe Asthma | 197 | 2025-03-24 | 2026-11-30 | in 102 d | 2026-06-15 |
| AZN | AstraZeneca | — | GRANITE: Airsupra Effectiveness in the Real WorldNCT07141277observationalBaseline demographics and clinical characteristics of patients receiving Airsupra and albuterol | — | Completed | Other: None (Observational study) | Asthma | 4,060 | 2025-07-09 | 2026-03-20actual | — | 2026-06-12 |
| AZN | AstraZeneca | — | Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05).NCT00242307change in lung function parameters. | Phase 2/3 | Completed | Drug: Roflumilast | Bronchial Asthma | 450 | 2004-05-01 | 2006-09-01actual | — | 2026-06-10 |
| AZN | AstraZeneca | — | Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).NCT00246922Long-term safety after 28 weeks treatment of Roflumilast at (total 52 weeks, 24 weeks of study APTA-2217-05 followed by 28 weeks) . | Phase 3 | Completed | Drug: Roflumilast | Bronchial Asthma | 150 | 2004-12-01 | 2007-01-01actual | — | 2026-06-10 |
| SNY | Sanofi | — | A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)NCT05070663observationalMedical history (including history of asthma) | — | Completed | — | Asthma | 105 | 2021-11-04 | 2024-03-14actual | — | 2026-06-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Registry of Asthma Patients Initiating DUPIXENT®NCT04287621observationalDemography | — | Completed | Drug: DUPIXENT® | Asthma | 718 | 2020-03-02 | 2026-04-27actual | — | 2026-06-04 |
| AZN | AstraZeneca | — | Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in KoreaNCT06998095observationalIncidence proportion of AEs, ADRs, SAEs, SADRs, unexpected AEs/ADRs and unexpected SAEs/SADRs | — | Not yet recruiting | — | Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps(CRSwNP) | 210 | 2026-11-28 | 2029-10-31 | in 1,168 d | 2026-06-04 |
| AZN | AstraZeneca | — | Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist DiagnosisNCT07245576observationalAccuracy of primary care asthma/COPD diagnosis using oscillometry (ALDS: R5, R20, R5-R20, X5, Ax) plus FeNO ≥50 ppb (Fenom PRO®/ALDS Pro) vs specialist gold standard; metrics: Cohen's kappa, agreement, sensitivity, specificity in overall, asthma, COPD | — | Recruiting | — | Asthma, COPD | 600 | 2025-12-26 | 2027-04-30 | in 253 d | 2026-05-27 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaNCT06572228Annualized severe asthma exacerbation rate | Phase 4 | Active, not recruiting | Drug: dupilumab, Matching Placebo, ICS/LABA | Asthma | 120 | 2024-08-26 | 2027-04-24 | in 247 d | 2026-05-22 |
| SNY | Sanofi | — | Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyNCT06033833Percentage of participants with treatment-emergent adverse events | Phase 2 | Active, not recruiting | Drug: Amlitelimab, Placebo | Asthma | 335 | 2023-09-05 | 2026-09-29 | in 40 d | 2026-05-20 |
| UPB | Upstream Bio Inc. | $375M | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 2 | Active, not recruiting | Drug: Verekitug, Placebo | Severe Asthma | 396 | 2025-05-21 | Sep 2027 | ≤ 406 d | 2026-05-14 |
| AZN | AstraZeneca | — | Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289Annualized asthma exacerbation rate | Phase 3 | Recruiting | Combination product: ICS-LABA, benralizumab, Placebo for Benralizumab | Eosinophilic Asthma | 400 | 2025-03-28 | 2028-11-03 | in 806 d | 2026-05-13 |
| AZN | AstraZeneca | — | Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaNCT06566885observationalChange in ACQ-5 score from baseline | — | Active, not recruiting | — | Severe Asthma | 125 | 2024-09-10 | 2026-09-30 | in 41 d | 2026-05-12 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12 | Phase 2 | Recruiting | Drug: PF-07275315 · Other: Placebo | Asthma | 252 | 2025-05-20 | 2027-03-08 | in 200 d | 2026-05-04 |
| UPB | Upstream Bio Inc. | $375M | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)NCT06196879Annual Asthma Exacerbation Rate (AAER) | Phase 2 | Completed | Drug: Verekitug (UPB-101), Placebo | Severe Asthma | 479 | 2024-02-27 | 2025-12-16actual | — | 2026-05-01 |
| AZN | AstraZeneca | — | A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With AsthmaNCT07525375Change from baseline in Forced Expiratory volume in one second (FEV1) at 1-hour post-dose measured at End of treatment (EoT) | Phase 2 | Recruiting | Combination product: GP MDI, BFF MDI, Placebo MDI | Asthma | 69 | 2026-04-14 | 2029-05-23 | in 1,007 d | 2026-04-22 |
| AZN | AstraZeneca | — | Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry StudyNCT06521229observationalTo describe the baseline demographic characteristics of outpatients with uncontrolled asthma in the Russian Federation in all patients and in the cohort of patients receiving fixed-dose combination (FDC) budesonide/salbutamol on Visit 2 | — | Recruiting | — | Uncontrolled Asthma | 9,000 | 2024-06-27 | 2026-09-30 | in 41 d | 2026-04-20 |
| SNY | Sanofi | — | Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe AsthmaNCT05097287Rate of change from week 8 to week 52 on post-BD FEV1 slope in FeNO population | Phase 4 | Active, not recruiting | Drug: Dupilumab, Placebo | Asthma | 1,339 | 2021-12-16 | 2027-03-16 | in 208 d | 2026-04-16 |
| AZN | AstraZeneca | — | A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.NCT05440656observationalChange in St. George's Respiratory Questionnaire (SGRQ) | — | Completed | Drug: Cohort | Severe Eosinophilic Asthma | 152 | 2022-06-29 | 2025-04-13actual | — | 2026-04-15 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseaseNCT05276570Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Completed | Drug: ARO-RAGE, Placebo | Asthma | 127 | 2022-06-29 | 2025-04-16actual | — | 2026-04-09 |
| AZN | AstraZeneca | — | Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)NCT05734339observationalTo evaluate the change in asthma control after initiation of benralizumab in a real-world Taiwan setting | — | Completed | — | Asthma | 43 | 2023-01-19 | 2025-02-03actual | — | 2026-04-01 |
| SNY | Sanofi | — | Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaNCT05421598results2026-03-30Annualized Rate of Severe Asthma Exacerbation Events Over 48 Weeks | Phase 2 | Completed | Drug: Amlitelimab, Placebo | Asthma | 437 | 2022-06-30 | 2024-10-11actual | — | 2026-03-30 |
| SNY | Sanofi | — | Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaNCT06102005Annualized rate of asthma exacerbation events | Phase 2 | Completed | Drug: Lunsekimig, Placebo | Asthma | 685 | 2023-10-16 | 2026-02-23actual | — | 2026-03-17 |
| AZN | AstraZeneca | — | A Study for Observing Severe Asthma in Patients Treated With TezepelumabNCT05677139observationalAsthma Control Questionnaire (ACQ-6) score | — | Completed | Other: None (Observational Study) | Asthma | 513 | 2022-12-13 | 2026-02-27actual | — | 2026-03-16 |
| AZN | AstraZeneca | — | Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma PatientsNCT05603845observationalChanges from baseline in Asthma Control Questionnaire (ACQ-6) | — | Completed | — | Severe Asthma | 291 | 2023-02-20 | 2025-04-10actual | — | 2026-03-10 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected PregnancyNCT04173442observationalRate of major structural defects | — | Completed | Drug: dupilumab | Atopic Dermatitis (AD), Asthma | 581 | 2018-10-24 | 2025-11-04actual | — | 2026-03-04 |
| AZN | AstraZeneca | — | A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsNCT06529419Time to first CompEx Asthma event | Phase 2 | Completed | Drug: AZD8630, Placebo · Device: Inhaler | Asthma | 537 | 2024-08-30 | 2026-02-04actual | — | 2026-03-02 |
| AZN | AstraZeneca | — | Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild AsthmaNCT06563102Change from baseline to maximum value of daily morning FeNO | Phase 4 | Completed | Combination product: Albuterol/Budesonide, Albuterol | Mild Asthma | 101 | 2024-09-11 | 2026-02-24actual | — | 2026-02-27 |
| APGE | Apogee Therapeutics, Inc. | $8.2B | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaNCT06920901Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Phase 1 | Active, not recruiting | Drug: APG777, Placebo | Asthma | 31 | 2025-03-27 | Sep 2026 | ≤ 41 d | 2026-02-17 |
| AZN | AstraZeneca | — | A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaNCT06502366Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29 | Phase 3 | Active, not recruiting | Drug: BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA | Asthma | 422 | 2024-07-22 | 2026-03-03 | — | 2026-02-13 |
| AZN | AstraZeneca | — | Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled AsthmaNCT05850494results2025-07-30Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 15 Minutes (AUC0-15 Min) Post-dose | Phase 3 | Completed | Drug: HFA MDI, HFO MDI | Asthma | 52 | 2023-05-02 | 2023-08-21actual | — | 2026-02-06 |
| AZN | AstraZeneca | — | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)NCT05202262results2026-01-28Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 24 | Phase 3 | Completed | Drug: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg, Open-label Symbicort TBH 320/9 μg | Asthma | 645 | 2022-01-12 | 2025-02-26actual | — | 2026-01-28 |
| AZN | AstraZeneca | — | A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)NCT05755906results2026-01-28Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12 | Phase 3 | Completed | Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day), BD MDI 160 μg BID (320 μg/day) | Asthma | 374 | 2023-02-27 | 2024-11-19actual | — | 2026-01-28 |
| AZN | AstraZeneca | — | PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway ObstructionNCT05555290results2026-01-27Part 1: Change From Mannitol Baseline Forced Expiratory Volume in the First Second (FEV1) Area Under the Curve (AUC [0-60 Min]) Post-mannitol Challenge 1 - Non-Inferiority Analysis | Phase 3 | Completed | Combination product: PT027, PT007 | Asthma | 190 | 2022-09-28 | 2024-11-18actual | — | 2026-01-27 |
| AZN | AstraZeneca | — | Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma CentresNCT06455462observationalAnnualised exacerbation rate | — | Completed | Drug: Tezepelumab | Severe Asthma | 352 | 2024-04-22 | 2025-11-25actual | — | 2026-01-21 |
| AZN | AstraZeneca | — | Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaNCT05251259Time to first CompEx Asthma event | Phase 2 | Completed | Drug: Atuliflapon, Placebo | Asthma | 670 | 2022-01-27 | 2026-01-07actual | — | 2026-01-14 |
| AZN | AstraZeneca | — | Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in SpainNCT07013760observationalSocio-demographic variables: Age (years), Gender (male, female, other); Smoking status (Current smoker, Ex- smoker, Non-smoker) and cumulative index (packs/year); Height (cm) and weight (kg); Body Mass Index (BMI) (kg/m 2 ) | — | Completed | — | Asthma | 420 | 2025-06-23 | 2025-12-19actual | — | 2026-01-12 |
| AZN | AstraZeneca | — | CARE FOR ALL：an Evaluation of an Asthma QIPNCT05440097results2026-01-02Change From Baseline in the Proportion of Patients With an ICS-based Maintenance and/or Reliever Treatment | Phase 4 | Completed | Other: QIP intervention | Asthma | 1,500 | 2022-07-29 | 2024-09-03actual | — | 2026-01-02 |
| AZN | AstraZeneca | — | Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe AsthmaNCT05274815results2025-12-11Proportion of the Participants Who Discontinued OCS Without Loss of Asthma Control at Week 28 and Week 52 | Phase 3 | Completed | Biological: Tezepelumab | Asthma | 305 | 2022-05-17 | 2024-09-09actual | — | 2025-12-11 |
| SNY | Sanofi | — | A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world SettingNCT06018441observationalChange from baseline in health-related quality of life (HRQoL), as measured by the St. George's Respiratory Questionnaire (SGRQ) | — | Completed | — | Asthma | 112 | 2023-10-03 | 2025-10-10actual | — | 2025-12-09 |
| SNY | Sanofi | — | Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)NCT03560466results2025-11-21Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs) | Phase 3 | Completed | Drug: Dupilumab (SAR231893/REGN668), Asthma controller therapies (incl. prednisone/prednisolone), Asthma reliever therapies | Asthma | 378 | 2018-06-21 | 2025-04-01actual | — | 2025-11-21 |
| AZN | AstraZeneca | — | Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABANCT06020014Time to first CompEx Asthma event | Phase 2 | Completed | Drug: AZD4604 · Other: Placebo | Asthma | 339 | 2023-11-16 | 2025-10-28actual | — | 2025-11-13 |
| ARWR | Arrowhead Pharmaceuticals | $12.4B | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseaseNCT05292950Number of Participants with Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor business decision | Drug: ARO-MUC5AC, Placebo | Asthma, Chronic Obstructive Pulmonary Disease | 78 | 2022-06-27 | 2024-11-12actual | — | 2025-11-05 |
| GENB | Generate Biomedicines | $2.0B | A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDNCT07116889Number of participants with treatment related adverse events as assessed by CTCAE 5.0 | Phase 1 | Active, not recruiting | Biological: GB-0895 (SC), GB-0895 (SC) · Drug: Placebo (SC), Placebo (SC) | Asthma, COPD (Chronic Obstructive Pulmonary Disease) | 156 | 2023-12-12 | May 2027 | ≤ 284 d | 2025-11-05 |
| SNY | Sanofi | — | EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsNCT04998604results2025-10-23Change From Baseline to Week 24 in Nasal Polyp Score | Phase 4 | Completed | Drug: Dupilumab, Omalizumab, Placebo | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 360 | 2021-09-27 | 2024-10-16actual | — | 2025-10-23 |
| AZN | AstraZeneca | — | Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaNCT06435273Change from baseline to end of investigational medicinal product (IMP) administration in expression of T2 and non-T2, and JAK1-related genes and gene signatures in bronchial brushings | Phase 2 | Completed | Drug: AZD4604, Placebo to AZD4604 | Asthma | 36 | 2024-08-05 | 2025-10-15actual | — | 2025-10-23 |
| AZN | AstraZeneca | — | Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and OutcomesNCT07159295observationalBaseline demographic and clinical characteristics of severe eosinophilic asthma patients treated with benralizumab | — | Completed | — | Severe Asthma | 74 | 2021-08-10 | 2022-11-03actual | — | 2025-10-21 |
| AZN | AstraZeneca | — | A Study of Inhaled AZD8630 in Adolescents With AsthmaNCT07065331Area under the serum concentration-time curve from time zero to 24 hours (AUC0-24) | Phase 1 | Completed | Drug: AZD8630 · Device: Dry powder inhaler | Asthma | 10 | 2025-06-11 | 2025-09-19actual | — | 2025-10-14 |
| AZN | AstraZeneca | — | A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With AsthmaNCT06795906Number of adverse events (AEs) and serious adverse events (SAEs) | Phase 1 | Completed | Drug: AZD8630 · Other: Placebo · Device: Saphira device | Asthma | 24 | 2025-01-28 | 2025-06-27actual | — | 2025-10-03 |
| AZN | AstraZeneca | — | Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in SpainNCT06487065observationalComorbidities (e.g., allergic rhinitis, nasal polyposis, gastroesophageal reflux, chronic obstructive pulmonary disease (COPD), atopic dermatitis and other eosinophilic conditions, conditions related to OCS chronic use, etc.) | — | Completed | — | Severe Asthma | 33 | 2024-06-17 | 2024-10-25actual | — | 2025-10-02 |
| AZN | AstraZeneca | — | Tezepelumab PRO StudyNCT05922891observationalMean change in ACQ-6 at week 52 from baseline | — | Completed | — | Asthma | 92 | 2023-09-27 | 2025-09-20actual | — | 2025-09-30 |
| HBC.OL | Hofseth Biocare ASA | — | Unrefined Salmon Oil as Dietary Supplement in Adult AsthmaticsNCT05137132Change of severe and moderate events | Not applicable | Completed | Dietary supplement: CARDIO®, Placebo | Asthma | 70 | 2022-04-01 | 2024-12-09actual | — | 2025-09-26 |
| AZN | AstraZeneca | — | PROPE Severe Asthma Study in EgyptNCT06283290observationalTo describe the prevalence (frequency) of OCS use among severe asthma patients as defined by chronic treatment and/or bursts of OCS use. | — | Completed | — | Severe Asthma | 201 | 2024-03-12 | 2024-11-28actual | — | 2025-09-26 |
| AZN | AstraZeneca | — | Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)NCT03373045observationalHealthcare utilization- hospitalizations, clinic Visits, and asthma exacerbations | — | Completed | — | Asthma | 18 | 2018-02-27 | 2025-02-14actual | — | 2025-09-24 |
| AZN | AstraZeneca | — | REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled AsthmaNCT06299306observationalProportion of severe asthma patients with an Asthma Impairment and Risk Questionnaire (AIRQ®) score at baseline, and at 6 and 12 months post enrollment. | — | Terminatedsponsor's stated reason: The early termination of the study is due to challenging recruitment of study sites and patients. | — | Asthma, Bronchial | 19 | 2024-05-07 | 2024-11-25actual | — | 2025-09-18 |
| JSPR | Jasper Therapeutics, Inc. | $25M | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic AsthmaNCT06592768To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns. | Drug: Briquilimab · Other: Placebo Comparator | Allergic Asthma | 17 | 2024-11-26 | 2025-08-11actual | — | 2025-09-16 |
| SNY | Sanofi | — | First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic ParticipantsNCT05366764Number of participants with adverse events (AEs) /TEAEs | Phase 1 | Completed | Drug: SAR443765, Placebo, Salbutamol or levosalbutamol | Asthma | 36 | 2022-06-08 | 2023-02-24actual | — | 2025-09-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Asthma is matched — 18 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Asthma
- Severe Asthma
- Bronchial Asthma
- Asthma, Bronchial
- Severe Eosinophilic Asthma
- Allergic Asthma
- Asthma Control Level
- Asthma, Exercise-Induced
- Uncontrolled Asthma
- Eosinophilic Asthma
- Allergic Asthma Due to Dermatophagoides Farinae
- Allergic Asthma Due to Dermatophagoides Pteronyssinus
- Asthma in Children
- Asthma,
- Exercise Induced Asthma
- Mild Asthma
- Moderate to Severe Asthma
- Severe Uncontrolled Asthma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Asthma” (a text search, wider than this page)